Vojtech Melenovsky
Vojtech Melenovsky, MD, PhD is an expert in Cardiology at Institute of Clinical and Experimental Medicine (Czechia). As of October 2026, ScienceLeadR ranks Vojtech Melenovsky in the top 1% of experts worldwide for Heart Failure, and in the top 1% of experts in Czechia for Obesity and Overnutrition. Vojtech Melenovsky has authored 387 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 8 of them ongoing. SLR score: 1,803 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Transplantation - Endocrinology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1994 - 2026
Number : 387
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| "Baseline Characteristics and Utilization of Medical Therapies in Acute Hospitalized and Chronic Heart Failure Patients Enrolled in GRASP-HF: Differences Between ICARe-HF and Non-ICARe-HF Centres". PMID 42867408 — mortality, heart failure, heart, hospital mortality, heart failure, systolic, therapeutics | Eur J Heart Fail | 2026 | 0 |
| Left Atrial Remodeling and Functional Maladaptations in Obesity: An Invasive Pressure-Volume Analysis. PMID 42670652 — atrial remodeling, heart failure, heart, stress, physiological, phenotype, atrial fibrillation, adiposity, echocardiography, obesity | Circ Heart Fail | 2026 | 0 |
| SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure. PMID 42668568 — sodium-glucose transporter 2 inhibitors, genes, fibrosis, heart failure, heart, cellular senescence, therapeutics, tissues, interleukin-10, adipose tissue, gene expression | J Mol Cell Cardiol Plus | 2026 | 0 |
| Clinical Implications of Resting Metabolic Rate in Heart Failure with Preserved Ejection Fraction. PMID 42508633 — exercise, stroke, cardiac output, low, heart failure, heart, heart failure, diastolic, obesity, hemodynamics, vasodilation | J Card Fail | 2026 | 0 |
| IL-1-Activated Inflammatory Cardiac Fibroblasts Exacerbate Acute Coxsackievirus B3 Myocarditis. PMID 42492293 — cells, myocarditis, interleukin-1, fibroblasts, infections | JACC Basic Transl Sci | 2026 | 0 |
Clinical Studies 27
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
8 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity 2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research | Phase 3 | Recruiting | 2026 |
| A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping function of the left side of the heart 2024-519525-38-00 — safety, heart failure, heart | Phase 3 | Not yet recruiting | 2025 |
| A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure 2023-509706-30-00 — safety, heart failure, heart | Phase 3 | Recruiting | 2024 |
| A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced mildly reduced ejection fraction and left ventricular hypertrophy 2024-515797-27-00 — hypertrophy, left ventricular, safety, heart failure, heart, hypertrophy, research | Phase 2 | Recruiting | 2025 |
| Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure NCT06331208 — exercise, hypertension, lung, hypertension, pulmonary, blood, pulmonary circulation, heart failure, tomography, vascular resistance, heart, pulmonary artery, arteries, spirometry, tomography, emission-computed, single-photon, metabolomics, ventilation, artificial intelligence, plasma | N/A | Recruiting | 2024 |
LeadR Networks
Main global connection map